Sign in to NCBI

Display Settings:

Format

Send to:

Choose Destination
Accession: PRJNA475477 ID: 475477

ESR1 mutations maintain higher ER pathway activity relative to vehicle and ERa-WT controls following treatment with Raloxifene or fulvestrant. (human)

See Genome Information for Homo sapiens
Navigate Up
This project is a component of the Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer.
Navigate Across
3 additional projects are components of the Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer..
66644 additional projects are related by organism.
The goal of the study was to understand whether mutations in ERa can promote resistance to various ERa antagonists of the SERD and SERM class. More...
AccessionPRJNA475477; GEO: GSE115564
Data TypeTranscriptome or Gene expression
ScopeMultiisolate
OrganismHomo sapiens[Taxonomy ID: 9606]
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo; Homo sapiens
SubmissionRegistration date: 11-Jun-2018
H3 Biomedicine
RelevanceMedical
Project Data:
Resource NameNumber
of Links
GEO DataSets1
GEO Data Details
ParameterValue
Data volume, Spots1968300
Data volume, Processed Mbytes43
Data volume, Supplementary Mbytes157

Supplemental Content

Related information

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI
Support Center